The diagnostics innovator has bagged a further $100 million in damages, but the country’s patent system has put unnecessary hurdles in the way, argues representative John Desmarais.
Pharma companies in India are struggling to enforce compounds that are covered by both genus and subsequent species patents. While the latest case involved a series of injunctions being vacated, the patent community is still unsatisfied by the lack of concrete judgments on this issue.
The ruling by the US Court of Appeals for the Federal Circuit limits analogous art, and innovators can leverage this precedent by adopting certain patent drafting methods
23 May 2023
The Supreme Court yesterday handed down one of the most anticipated patent decisions in decades
19 May 2023
But there’s no clarity yet on the new section’s competencies
19 May 2023
The Munich Regional Court has also granted a permanent injunction against NanoString Technologies
18 May 2023
The decision, leaving in place a polarising Federal Circuit decision, has significant implications for life sciences IP strategies
16 May 2023
Opinion: Pharma and biotech patent professionals must adapt to new challenges and opportunities
13 May 2023
Following a catastrophic loss of exclusivity stateside, the company has received a boost in the EU
12 May 2023
Delaware jury rules against the federal government in a big-money patent infringement suit being closely watched by policymakers.
11 May 2023
Following a lull in lawsuits, several new biologics have become the subject of litigation in recent months
05 May 2023
The vaccine maker has suffered another setback, but its fight to deflect infringement responsibility to the US government continues
02 May 2023
Unlock unlimited access to all IAM content
